Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis

• Published in: Journal of dermatology Vol. 42; no. 2; pp. 129 - 139
• Main Authors: Murata, Yoko, Song, Michael, Kikuchi, Hisayuki, Hisamichi, Katsuya, Xu, Xie L., Greenspan, Andrew, Kato, Mai, Chiou, Chiun-Fang, Kato, Takeshi, Guzzo, Cynthia, Thurmond, Robin L., Ohtsuki, Mamitaro, Furue, Masutaka
• Format: Journal Article
• Language: English
• Published: Tokyo Blackwell Publishing Ltd 01.02.2015; Wiley Subscription Services, Inc
• Subjects: atopic dermatitis; H4 receptor; itch; Japan
• ISSN: 0385-2407; 1346-8138
• DOI: 10.1111/1346-8138.12726

This trial was conducted to evaluate the safety and efficacy of the H4R‐antagonist JNJ‐39758979 in adult Japanese patients with moderate atopic dermatitis (AD). Eligible patients were randomly assigned to JNJ‐39758979 300 mg, 100 mg or placebo once daily for 6 weeks in this phase 2a, double‐blind, multicenter, placebo‐controlled study. Primary efficacy was assessed via week‐6 Eczema Area and Severity Index (EASI) scores. Secondary efficacy assessments included Investigator's Global Assessment (IGA) and patient‐reported outcome (PRO) pruritus assessments (Pruritus Categorical Response Scale [PCRS], Pruritus Numeric Rating Scales [PNRS], Pruritus Interference Numeric Rating Scale [PINRS] and Subject's Global Impressions of Change in Pruritus [SGICP]). Eighty‐eight of 105 planned patients were randomized before the study was stopped and unblinded for safety reasons. The study did not meet the primary end‐point. However, numerical improvements (i.e. decreases) in median EASI were observed with JNJ‐39758979 100 mg (−3.7) and 300 mg (−3.0) versus placebo (−1.3) at week 6. Nominally significant improvements across PRO PCRS, PNRS and SGICP assessments were consistently observed, particularly with JNJ‐39758979 300 mg. Safety, including adverse events (AE), was comparable between JNJ‐39758979 and placebo with the exception of two patients (both receiving JNJ‐39758979 300 mg) with serious AE of neutropenia, leading to premature study discontinuation. No deaths were reported. Except for neutropenia, no clinically relevant changes in laboratory values were observed. Although not conclusive, findings suggest H4R‐antagonism may be beneficial for AD, particularly in controlling pruritus. JNJ‐39758979 appears to be associated with drug‐induced agranulocytosis, likely an off‐target effect.